Ken Flanagan

Ken Flanagan has a diverse and extensive work experience in the field of biology. Ken is currently working as the Head of Discovery Biology at EpiBiologics since May 2023. Prior to that, they served as the Head of Biology at Therini Bio, Inc. (formerly MedaRed, Inc.) from April 2021 to March 2023. Ken also gained research project management experience at Oncopeptides AB from May 2019 to March 2022. Ken has founded Wenbli Therapeutics in May 2019 and held the role of Founder until 2022. Before that, Ken worked at Prothena Biosciences as the Director and Head of Cell Biology from December 2012 to June 2018. Ken started their career as a Staff Scientist at Elan Pharmaceuticals from April 2008 to December 2012 and completed a postdoctoral position at Genentech from October 2004 to April 2008. Ken began their academic journey as a Graduate Student at Columbia University from August 2001 to 2004.

Ken Flanagan earned a Bachelor of Science (BS) degree in Nutrition from Cornell University, where they studied from 1994 to 1998. Ken then pursued a Master of Science (MS) degree in Immunology at Albert Einstein College of Medicine, completing their studies from 1998 to 2001. Following this, Ken attended Columbia University Vagelos College of Physicians and Surgeons, where they obtained their Doctor of Philosophy (PhD) degree in Immunology between 2001 and 2004.